BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35384874)

  • 1. Comparison of the Clinicopathologic Features and T-Cell Infiltration of B7-H3 and B7-H4 Expression in Triple-negative Breast Cancer Subtypes.
    Kim NI; Park MH; Cho N; Lee JS
    Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):246-256. PubMed ID: 35384874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7-H3 and B7-H4 Expression in Breast Cancer and Their Association with Clinicopathological Variables and T Cell Infiltration.
    Kim NI; Park MH; Kweon SS; Lee JS
    Pathobiology; 2020; 87(3):179-192. PubMed ID: 32088722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration.
    Kim GE; Kim NI; Park MH; Lee JS
    Tumour Biol; 2018 Nov; 40(11):1010428318815032. PubMed ID: 30486739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of B7-H3 and B7-H4 Expression in Ductal Carcinoma In Situ of the Breast With Clinicopathologic Features and T-Cell Infiltration.
    Kim NI; Park MH; Lee JS
    Appl Immunohistochem Mol Morphol; 2020; 28(10):767-775. PubMed ID: 31714284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma.
    Lu Z; Zhao ZX; Cheng P; Huang F; Guan X; Zhang MG; Chen HP; Liu Z; Jiang Z; Zheng ZX; Zou SM; Wang XS
    Mod Pathol; 2020 Nov; 33(11):2330-2340. PubMed ID: 32514163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
    MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
    J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes.
    Sanuki F; Mikami Y; Nishimura H; Fujita Y; Monobe Y; Nomura T; Taira N; Moriya T
    Breast Cancer; 2023 Nov; 30(6):1041-1053. PubMed ID: 37642903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
    Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
    Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
    [No Abstract]   [Full Text] [Related]  

  • 10. Co-deficiency of B7-H3 and B7-H4 identifies high CD8 + T cell infiltration and better prognosis in pancreatic cancer.
    Si S; Wang L; Cao H; Xu Y; Zhan Q
    BMC Cancer; 2022 Feb; 22(1):211. PubMed ID: 35219310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
    Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
    Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
    Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
    Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subclassifying triple-negative breast cancers and its potential clinical utility.
    Lian J; Ma HX; Xu EW; Bu P; Yun KM; Xi YF
    Virchows Arch; 2022 Jul; 481(1):13-21. PubMed ID: 35471664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
    Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
    J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer.
    Yim J; Koh J; Kim S; Song SG; Ahn HK; Kim YA; Jeon YK; Chung DH
    Eur J Cancer; 2020 Jul; 133():74-85. PubMed ID: 32447027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic values of B7-H3, B7-H4, and HHLA2 expression in human pancreatic cancer tissues based on mIHC and spatial distribution analysis.
    Zhu Y; Chen J; Liu Y; Zheng X; Feng J; Chen X; Jiang T; Li Y; Chen L
    Pathol Res Pract; 2022 Jun; 234():153911. PubMed ID: 35489125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy.
    Cheng N; Bei Y; Song Y; Zhang W; Xu L; Zhang W; Yang N; Bai X; Shu Y; Shen P
    Biochem Pharmacol; 2021 Jan; 183():114298. PubMed ID: 33153969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer.
    Lv C; Han S; Wu B; Liang Z; Li Y; Zhang Y; Lang Q; Zhong C; Fu L; Yu Y; Xu F; Tian Y
    Front Immunol; 2022; 13():984172. PubMed ID: 36159808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of "Basal-like" Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative Breast Cancer.
    Čeprnja T; Tomić S; Perić Balja M; Marušić Z; Blažićević V; Spagnoli GC; Juretić A; Čapkun V; Vuger AT; Pogorelić Z; Mrklić I
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node-Negative, p53-Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal Adenocarcinoma.
    Chen X; Zhang Y; Mo S; Ma H; Lu Z; Yu S; Chen J
    Arch Pathol Lab Med; 2023 Apr; 147(4):465-473. PubMed ID: 35862858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.